Suzhou Ribo jumps on first milestone achievement from Madrigal tie-up

Madrigal Pharmaceuticals

02/07/2026 06:03

** Suzhou Ribo Life Science 6938.HK shares jump 10.7% to HK$51.9, their highest level since June 9
** China-based oligonucleotide developer on course for biggest one-day pct gain since April 1 
** Co says first candidate drug nomination milestone achieved in siRNA partnership with Madrigal Pharmaceuticals Inc MDGL.O to advance cutting-edge RNA therapeutics for liver diseases, with focus on metabolic dysfunction-associated steatohepatitis (MASH) 
** Company and Madrigal aim to develop promising siRNA drug by utilizing the company’s liver-targeting RiboGalSTAR platform, to deliver more targeted and effective treatments for MASH patients - co
** MASH is a serious liver disease that can progress to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality
** Since January 9 debut, Suzhou Ribo down 13.7% from offer price 

(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))